Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin by DESCHAMPS, Frédéric et al.
HAL Id: hal-02331684
https://hal.archives-ouvertes.fr/hal-02331684
Submitted on 24 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Pickering-Emulsion for Liver Trans-Arterial
Chemo-Embolization with Oxaliplatin
Frédéric Deschamps, Kathleen Harris, Li Weiguo, Laurence Moine, Lambros
Tselikas, Thomas Isoardo, Robert Lewandowski, Angelo Paci, Thierry de
Baere, Nicolas Huang, et al.
To cite this version:
Frédéric Deschamps, Kathleen Harris, Li Weiguo, Laurence Moine, Lambros Tselikas, et al.. Pickering-
Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. CardioVascular and Inter-
ventional Radiology, Springer Verlag, 2018, 41 (5), pp.781-788. ￿10.1007/s00270-018-1899-y￿. ￿hal-
02331684￿
1 
 
Pickering Lipiodol-emulsion for liver TACE with oxaliplatin 
 
Deschamps F1, Harris KR2, Li W2, Moine L3, Tselikas L1, Isoardo T3, Lewandowski 
RJ4, Paci A5, de Baere T1, Salem R4 and Larson AC2. 
 
1 Gustave Roussy, Université Paris-Saclay, Département de radiologie 
Interventionnelle, Villejuif, France. 
2 Department of Biomedical Engineering, Northwestern, University, Chicago, USA.  
3 Institut Galien, CNRS UMR 8612, Université Paris-Saclay, Faculté de Pharmacie, 
Châtenay-Malabry, France  
4 Department of Radiology, Section of Interventional Radiology, Northwestern 
University, Chicago, USA. 
5 UMR 8203, Université Paris-Saclay, Villejuif, France. 
 
Corresponding author: Frederic Deschamps, MD 
 Institution: Gustave Roussy, Interventional Radiology department 
 Mail: 114 rue Edouard Vaillant, 94805 Villejuif, France 
 Tel: 0033 1 42 11 67 25 
 Fax: 0033 1 42 11 52 78 
 Email: frederic.deschamps@gustaveroussy.fr 
 
Manuscript type: Laboratory investigation 
 
The authors declare they have no conflict of interest. 
This study was supported by NIH funding source (n°???) 
2 
 
Acknowledgements: The authors thank Woo-Ram Park, Xiaoke Huang, Soojeong 
Cho and Lionel Mercier for their previous technical support. Metal analysis was 
performed at the Northwestern University Quantitative Bio-element Imaging Center 
generously supported by NASA Ames Research Center Grant NNA04CC36G. 
 
  
3 
 
Pickering Lipiodol-emulsion for liver TACE with oxaliplatin 
 
Purpose 
Polylactic-co-glycolic acid (PLGA) nanoparticles (Nps) adsorb at the water/oil 
interface to stabilize emulsion (Pickering-emulsion). This study aimed to compare the 
release profiles of oxaliplatin from Pickering-emulsion and from Lipiodol-emulsion. 
 
Materials/methods 
Pickering-emulsions and Lipiodol-emulsions were both formulated with 
oxaliplatin (5mG/mL) and Lipiodol (Water/oil ratio: 1/3). For Pickering-emulsion only, 
PLGA-Nps (15mG/mL) were dissolved into oxaliplatin before formulation. In-vitro 
releases of platinum from both emulsions were evaluated. Then, 0.625 mG 
oxaliplatin was injected in left hepatic arteries of 18 rabbits bearing VX2 liver tumors 
using either 0.5 mL Pickering-emulsion (n=10) or 0.5 mL Lipiodol-emulsion (n=8). In 
each group, half rabbits were sacrificed at 1h and half at 24h. Platinum’ plasmatic 
pharmacokinetic and quantification in tissues (tumors and left-liver lobes) were 
measured (ICP-MS mass-spectrometry) and compared. 
 
Results 
In-vitro, Pickering-emulsion demonstrated a slow oxaliplatin’ release compared 
to Lipiodol-emulsion (15.8 ±3.0% vs. 85.3 ±3.3% at 24h). The platinum plasmatic-
peak and the area under the curve were significantly lower with Pickering-emulsion, 
respectively 0.24 ±0.07 nG/mL vs. 0.53 ±0.20 nG/mL, p=0.01 and 9.7 +/-2.9 vs. 15.6 
+/-7.3, p=0.03. Platinum’ concentration in tumors was not different between the 2 
emulsions neither at 1h (8.6 ±3.3 vs. 15.7 ±10.4 nG/mG, p=0.08) nor at 24h (5.1 ±4.8 
vs. 2.2 ±1.9, p=0.06). The ratio tumors/left-livers platinum’ concentrations was 
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significantly higher with Pickering-emulsion at 1h (33.2 ±14.9 vs.18.0 ±10.8, p=0.02) 
and 24h (43.4 ±42.9 vs. 14.5 ±6.6, p=0.04).  
 
 
Conclusion 
 Slow release of oxaliplatin from Pickering-emulsion results in significant 
decrease of systemic exposure and similar concentrations in the tumors at 1h and 
24h.  
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Introduction 
A drug delivery platform is currently used during liver Trans Arterial Chemo-
Embolization (TACE). It acts as a transient reservoir, allowing slow release of the 
chemotherapy in the tumors’ supply for a prolonged exposure of the cancer’ cells 
while minimizing systemic effects. Lipiodol and drug eluding beads are the two drug 
delivery platforms, currently used in clinical practice for TACE of hepatocarcinoma 1 
or liver metastases from neuroendocrine or colorectal cancers. Various anticancer 
drugs such as doxorubicin, epirubicin, irinotecan, mitomycin C and cisplatin have 
been evaluated with one or the other or the both platforms.   
Lipiodol (Guerbet, Aulnay-sous-bois, France) is an oily based radio-opaque 
contrast agent that is use as a drug delivery platform because of its radio-opacity and 
its preferential tumor uptake compared to surrounding liver tissue2. Since most 
anticancer drugs are water-soluble, the vectorization mechanism consists in 
formulating a water-in-oil emulsion between the chemotherapy (aqueous-phase) and 
the Lipiodol (oily-phase)3. However, the release of chemotherapy occurs quite rapidly 
because lipiodol-emulsions have relatively poor stability. Within a few minutes – 
hours according the chemotherapy, the two phases of the emulsion separate and 
almost the entire water-soluble drug disappears very rapidly from the Lipiodol, 
resulting in high chemotherapy systemic exposure and inadequacy between the 
deposit of Lipiodol and of chemotherapy deposit 4. 
Drug eluding beads are polyvinyl alcohol-based hydrogel beads that can be 
loaded with chemotherapy. The presence of the anionic sulphonate group enables 
the sequestering of positively charged drugs only (Coulomb charge interactions). 
Thus, doxorubicin, epirubicin or irinotecan are the only chemotherapies that can be 
used in clinical practice. In addition, because of variable ionic interaction’ intensities 
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between beads and the chemotherapy, the release could be either incomplete and 
very slow (doxorubicin) or complete and very fast (irinotecan)5. Finally, the beads are 
not only a drug delivery platform but also an embolic medical device (different sizes 
available, ranging from 70 up to 700 μm) that blocks the arterial flow. This property 
helps in further increasing the tumor drug exposure but can induce hypoxia and 
unexpected development of new tumor blood vessels (tumor neo-angiogenesis). 
Although calibrated drug eluting beads have been developed to standardize the 
TACE procedure, the choice of loadable chemotherapies is limited to anionic drugs. 
Moreover, the release kinetics could be affected by chemical rearrangements of the 
drug inside the microsphere.  
We have therefore developed a new concept of drug delivery platform that 
allows 1) the loading of various types of chemotherapies independently of their 
chemical structure and 2) their controlled release while keeping the value of Lipiodol 
in terms of a radio-opacity, preferential tumor’ uptake6 and transient vessels’ 
occlusion7. The principle is based on the Pickering technology8,9 that uses solid 
particles instead of surfactants to stabilize the water droplets. Pickering emulsions 
are known to display a high stability against coalescence The use of solid particles 
(Pickering technology) in the formulation of an emulsion avoids the use of toxic 
synthetic surfactants and results in very stable interfaces between the aqueous 
phase and the oily phase. 
The purpose of this study is to compare the release profiles of oxaliplatin from 
Pickering-emulsion and Lipiodol-emulsion. 
 
Pickering emulsions stabilized by the irreversible adsorption of tiny solid particles at 
the interface have been drawn lots of attention since its appearance. 
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Pickering emulsion showed a special number of advantages over conventional 
surfactant emulsion, namely: (i) a high stability thanks to the robust and reproducible 
formulations,(ii) reduced  foaming problems and (iii) a lower toxicity (at least 
compared to certain surfactants) 
Materials/ methods 
Two successive studies were performed to compare Pickering-emulsion and 
Lipiodol-emulsion. The first one was designed to compare the in vitro release profile 
of oxaliplatin from the 2 emulsions.  The second study was an animal study designed 
to compare the plasmatic pharmacokinetics and tissues exposures of oxaliplatin in 
rabbit implanted with VX2 liver tumors. 
 
Formulation of the emulsions: 
Two different types of water-in-oil emulsions were formulated: Lipiodol-
emulsion and Pickering-emulsion.  
For both emulsions, the oily-phase was composed with Lipiodol and the 
aqueous phase was composed with oxaliplatin (5 mG/mL). The addition of polylactic-
co-glycolic acid (PLGA) nanoparticles in the aqueous-phase of Pickering-emulsion 
(15 mG/mL) was the only difference between the 2 emulsions. These nanoparticules 
adsorb at the water/oil interface to stabilize the emulsion (Figure-1). Oxaliplatin was 
the chosen chemotherapy in this study for two main reasons. First, several studies 
has already demonstrated that hepatic arterial infusion (HAI) of oxaliplatin is safe and 
effective in animal models and in humans. Second, the most appropriate drug 
delivery platform for oxaliplatin has not been investigated yet. 
Water-in-oil emulsions were formulated by continuous injection of 1 volume of 
aqueous phase in 3 volumes of oily phase with an electric syringe-pump (flow-rate of 
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1 mL per minute) during repetitive pumping of two 10-mL syringes through a three-
way stopcock10. 
 
In vitro study: 
In-vitro release of platinum from the 2 emulsions was evaluated. We did the 
experiments twice for each emulsion: an aliquot of 0.8 mL of emulsion 
(corresponding to1 mG of oxaliplatin or to 0.49 mG of platinum) was loaded into mini 
GeBAflex tubes (molecular weight cut-off: 12–14 kDa; Gene Bio-Application Ltd., 
Kfar Hanagide, Israel). Those tubes were immersed in 40 ml of buffer solution 
(acetate buffer 25 mM, pH 6.8) and incubated in a shaking bath (37°C) rotated at a 
speed of 150 rpm. At predetermined times (1h, 4h, 24 h, 48h, 72h, 1 week, 2 weeks 
and 1 month), 0.5 ml of buffer solution were collected for platinum quantification. 
 
Animal study: 
This study was performed in accordance with our institutional Animal Care and 
Use Committee guidelines. VX2 liver tumors were percutaneously implanted in New 
Zealand White rabbits under general anesthesia (Intramuscular injections of 
Ketamine 20-40mg/kg and xylazine 3-5mg/kg, Isoflurane 3-5% for induction and 1.5-
3% for maintenance mixed with O2 at 1L/min). For this purpose, 1–2 mm freshly 
harvested tumor fragments, coming from the hind limb tumors of a donor rabbits 
were implanted under ultrasound guidance through a 18G needle and in 3 different 
locations of the left liver lobe. 1 week after the liver tumors’ implantations, MR 
checkup scans were performed to confirm tumors growth and location in liver. 
Two weeks after the liver tumors’ implantations, TACE procedures were 
performed by an experienced interventional radiologist (FD), under general 
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anesthesia and under fluoroscopic guidance (OEC 9800 Plus Mobile C-arm, 
Milwaukee, Wisconsin, USA). The femoral artery was surgically exposed and 
catheterized with a 4F vascular sheath using a Seldinger approach. A micro-catheter 
(2.4F Merit Maestro Merit medical®, South Jordan, UT, USA) was used to selectively 
engage the left hepatic branch (Figure-2) and to inject 0.5 ml of emulsion 
corresponding to 0.625 mG of oxaliplatin. Attention was given to avoid any injection 
in the right hepatic artery and additional embolization with gelatin sponge was 
consider only in case of persistent flow in the left hepatic branch after completion of 
the injection. 
Heparinized systemic blood samples (2 mL) were collected from the vascular 
sheath 5, 10, 20, 30 and 60 minutes after the injection of the emulsion to measure 
the plasmatic pharmacokinetics of oxaliplatin. The procedures were either non-
recovery procedures (sacrifice at 1 hour, immediately after the last blood sample 
collection) or recovery procedures with sacrifice at 24 hours. Four different groups of 
rabbits were considered according to the type of emulsion they received and 
according to the delay before sacrifice:  
- Group-1: rabbits received Lipiodol-emulsion and were sacrificed 1 hour after the 
injection. 
- Group-2: rabbits received Pickering-emulsion and were sacrificed 1 hour after the 
injection. 
- Group-3: rabbits received Lipiodol-emulsion and were sacrificed 24 hours after the 
injection. 
- Group-4: rabbits received Pickering-emulsion and were sacrificed 24 hours after the 
injection. 
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Immediately after sacrifice, post-TACE MR scans (3T Magnetom Skyra; 
Siemens, Erlangen, Germany) using a 15 channels knee coil, was performed for 
each rabbit to measure and enumerate the liver tumors (Figure-2). Then, livers were 
resected. Tissues samples from the right and left liver lobes, as well as all the tumors 
were dissected separately and homogenized with a blender for platinum 
quantification. 
 
Platinum quantification: 
Quantification of platinum was accomplished using mass spectrometry ICP-
MS of acid digested samples.  Specifically, blood and tissues samples were digested 
in concentrated trace nitric acid (> 69%, Thermo Fisher Scientific, Waltham, MA, 
USA) and placed at 60 °C for 24 hours to allow for complete sample digestion.  Ultra 
pure H2O (18.2 MΩ∙cm) is then added to produce a final solution of 3.0% nitric acid 
(v/v) and 4.0% hydrochloric acid (v/v) in a total sample volume of 5 mL. Quantitative 
standards were made using individual 1000 µg/mL Pt elemental standards (Inorganic 
Ventures, Christiansburg, VA, USA) which were combined to create a 100 ng/mL 
mixed element standard in 2.0% nitric acid (v/v) and 4.0% hydrochloric acid (v/v) in a 
total sample volume of 50 mL.  ICP-MS was performed on a computer-controlled 
(QTEGRA software) Thermo iCapQ ICP-MS (Thermo Fisher Scientific, Waltham, 
MA, USA) operating in STD mode and equipped with a ESI SC-2DX PrepFAST 
autosampler (Omaha, NE, USA). Internal standard was added inline using the 
prepFAST system. Online dilution was also carried out by the prepFAST system and 
used to generate calibration curves consisting of 100, 50, 20, 10, 5, 2, 1 ng/mL Pt.  
Each sample was acquired using 1 survey run (10 sweeps) and 3 main (peak 
jumping) runs (40 sweeps).  
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Statistical Analysis 
Data were presented as the mean value ± SD. Prism® software version 5.0 
was used to determine the Area Under the Curve (AUC) and to assess differences 
between means (t-test). P<0.05 was considered statistically significant.  
 
Results 
In vitro study: 
The platinum release profiles of the two different emulsions are shown in 
Figure-3. Lipiodol-emulsion demonstrated a rapid drug release compared with 
Pickering-emulsion. The percentage of platinum released from Lipiodol-emulsions 
and Pickering-emulsions were respectively: 12.0 ± 6% vs. 1.5 ± 0.2% at 1 h, 50.0 ± 
13.8% vs. 4.7 ± 0.9% at 4h, 85.3 ± 3.3% vs. 15.8 ± 3.0% at 24h. Interestingly, the 
release of platinum from the Lipiodol-emulsions was almost complete after 24h 
whereas it was still on going from the Pickering-emulsions after 1 month (72.0 ± 
2.1%). 
 
Animal study: 
A total of 18 rabbits (3.5 ± 0.3 kG) bearing a total of 33 liver VX2 tumors 
received selective left hepatic artery injection of 0.5 mL emulsion. No additional 
embolization with gelfoam was performed since the flow was already completely 
stopped by the emulsion. Nine rabbits were sacrificed at 1 hour and 9 rabbits were 
sacrificed at 24 hours. Four rabbits bearing 6 tumors were included in group-1, 5 
rabbits bearing 9 tumors in group-2, 4 rabbits bearing 9 tumors in group-3 and 5 
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rabbits bearing 9 tumors in group-4. The maximal tumor diameter was 15.0 ±6.4 mM 
without statistical difference between the 4 groups. 
 
Plasmatic pharmacokinetics of platinum 
Plasmatic pharmacokinetics of platinum after injection of the two emulsions 
are shown in Table-1 and Figure-4. We observed a significantly lower peak of 
platinum concentrations in the blood (Cmax) after injection of Pickering-emulsion 
(0.24 ±0.07 nG/mL) compared to Lipiodol-emulsion (0.53 ±0.2 nG/mL, p<0.01). The 
AUC at 1 hour was significantly lower for the Pickering-emulsion (9.7 ±2.9 vs. 15.6 
±7.3, p= 0.03).  
 
Platinum concentration in livers and tumors tissues  
Platinum concentrations in livers and tumors tissues are respectively 
presented in Table-1 and in Table-2. We observed a significantly lower concentration 
of platinum in the left liver lobe for Pickering-emulsion (0.29 ±0.07 nG/mG) compared 
to the Lipiodol-emulsion at 1 hour (1.29 ±0.77 nG/mG, p=0.04).  No difference was 
observed for the platinum’ concentration in right lobe between the different groups. 
The platinum’ concentrations in tumors were not significantly different between the 
Pickering-emulsion and the Lipiodol-emulsions, neither at 1 hour (8.6 ±3.3 vs. 15.7 
±10.4 nG/mG, p=0.08) nor at 24h (5.1 ±4.8 vs. 2.2 ±1.9, p=0.06). The platinum’ 
concentrations ratio between the tumor and the left liver was significantly higher with 
Pickering-emulsion compared to Lipiodol-emulsion at 1 hour ((33.2 ±14.9 vs. 18.0 
±10.8, p=0.02) and at 24 hours (43.4 ±42.9 vs. 14.5 ±6.6, p=0.04).  
 
Discussion 
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The terms ‘‘water-in-oil emulsion’’ refers to fine droplets’ dispersions of an 
aqueous-phase in a continuous oily-phase. The high interfacial energy of the 
dispersed droplets in the oily-phase contributes to thermodynamic instability and 
results in a coalescence process when droplets bump into each other and combine to 
form a larger droplet, so the average droplet size increases over time. However, 
stable Lipiodol-emulsion are necessary for TACE, allowing slow release of the 
chemotherapeutic agent into the liver’ tumor feeders for prolonged exposure, while 
minimizing systemic exposure11,12,13. Stable emulsions can be obtained using 
substances known as emulsifiers that are able to decrease the interfacial tension 
between the two phases and are usually included in emulsion formulations. Until 
now, synthetic surfactants have been used to stabilize Lipiodol-emulsions11. 
However, these surfactants raise directly or indirectly toxicity issues. On the other 
hand, Pickering-emulsion uses solid particles as emulsifiers. The adsorption of the 
solid particles at the water/oil interface lead to the formation of a protective film that 
resist droplet coalescence and phase separation. The low toxicity and high stability of 
Pickering-emulsions lend unique properties when compared against classical 
emulsions stabilized by synthetic surfactants and make them very attractive 
especially for biomedical applications such as TACE. 
 
We demonstrated that the use of fully biodegradable and biocompatible solid 
PLGA-nanoparticles in the formulation of emulsion results in a slow release of the 
oxaliplatin in-vitro. Indeed, the release of oxaliplatin from Lipiodol-emulsion was 
almost complete within 24 hours whereas it was only 15% when nanoparticules were 
added into the aqueous-phase. Based on our in-vitro study, we can also see that 
after 1 month, the total release of oxaliplatin from the Pickering-emulsion was around 
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72%. This slow release results in a significant decrease of the systemic exposure in-
vivo with a significant decrease of the plasmatic peak and of the area under the 
curve. Interestingly, this slow release doesn’t result in any significant difference in the 
tumor drug exposure, neither at 1 hour nor at 24 hours. We can observe a trend for 
higher platinum concentration in the tumor with Lipiodol-emulsion at 1 hour. Although 
non significant, this difference is consistent with the “bolus” release of oxaliplatin from 
the Lipiodol-emulsion demonstrated in-vitro. On the opposite, there is a trend for 
higher platinum concentration in the tumor with Pickering-emulsion at 24 hours. This 
prolong tumor exposure is consistent with the slow release of oxaliplatin 
demonstrated in-vitro. Interestingly, Pickering-emulsion keeps the value of the 
Lipiodol in terms of predominant accumulation in hyper vascularized liver tumors. We 
found that the platinum’ concentration ratio between the tumors and the left liver lobe 
was as high as 33.2 ±14.9 at 1 hour, significantly higher than the ratio obtained with 
Lipiodol-emulsion (18.0 ±10.8, p=0.02). 
Oxaliplatin is an effective chemotherapy for patients suffering from colorectal 
cancer. The Hepatic Arterial Infusion (HAI) of oxaliplatin and its association with 
systemic chemotherapy has yielded overall response rate of 64% in patients having 
survived one or more lines of IV chemotherapy14 and 62% in patients who have 
progressed on IV oxaliplatin15. In addition, HAI of oxaliplatin limits systemic and 
especially neurological toxicities, thanks to a greater hepatic clearance. The HAI of 
oxaliplatin has demonstrated significant pharmacokinetic advantages over the 
systemic route (IV) in rabbit VX2 liver tumor models16. It has been demonstrated that 
HAI of oxaliplatin results in tissue concentrations that are significantly higher in the 
tumor versus healthy hepatic tissue in a ratio of 4.3 at 24h. In our study this ratio was 
even higher at 24h, with a value of 43.4 ± 42.9 for Pickering-emulsions and 14.5 ± 
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6.6 for Lipiodol-emulsions, suggesting a real potential benefit of using a drug delivery 
platform for the HAI of oxaliplatin in terms of tumor response and systemic toxicities. 
 
We acknowledge some limitations. The first one is that we consider Lipiodol-
emulsion as a gold standard to evaluate the release of oxaliplatin from Pickering-
emulsion. However, there is no other drug delivery system that we could have used 
for comparison since oxaliplatin cannot be loaded in drug eluding beads so far. A 
high ratio of Lipiodol/oxaliplatin (3/1) and a continuous and slow incorporation of 
oxaliplatin in the Lipiodol were considered in order to obtain the best stability of the 
Lipiodol-emulsion3,10. Another limitation is that no embolic agent has been injected 
during TACE procedures. However, the flows in the arteries were always completely 
stopped at the end of the emulsion’ injections and additional embolizations would 
have resulted in back-flow in extra-hepatic arteries. In addition, we believed that 
additional embolizations would have introduced bias for the evaluation of the 
oxaliplatin’ release from the emulsions.  
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 Emulsions:  
 Conventional Pickering  
 Pharmacokinetic n= 8 rabbits n= 10 rabbits  
C max (nG/mL) 0.53 ± 0.2 0.24 ± 0.07 p<0.01 
AUC 15.6 ± 7.3 9.7 ± 2.9 p=0.03 
 Sacrifice: H+1 n= 4 rabbits (group-1) n= 5 rabbits (group-2)  
Platinum (nG/mG) - Left liver lobe 1.29 ± 0.77 0.29 ± 0.07 p=0.04 
 - Right liver lobe 0.76 ± 0.49 0.28 ± 0.12 p=0.07 
 Sacrifice: H+24 n= 4 rabbits (group-3) n= 5 rabbits (group-5)  
Platinum (nG/mG) - Left liver lobe 0.14 ± 0.10 0.15 ± 0.08 p=0.4 
 - Right liver lobe 0.09 ±0.05 0.10 ± 0.02 p=0.3 
Table-1: Mean platinum concentration (nG/mG) in liver tissues according to the type 
of emulsion injected and according to the delay before sacrifice. 
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 Emulsions:  
 Conventional Pickering  
 Sacrifice: H+1 n= 6 tumors (group-1) n= 9 tumors (group-2)  
Maximal tumor diameter (mM) 14.1  ± 11.1 16.0 ± 5.9 p=0.6 
Platinum : - in tumors (nG/mG) 15.7  ± 10.4 8.6 ± 3.3 p=0.08 
 
- ratio tumor/ left liver lobe 18.0 ± 10.8 33.2 ± 14.9 p=0.02 
 Sacrifice: H+24 n= 9 tumors (group-3) n= 9 tumors (group-4)  
Maximal tumor diameter (mM) 15.0 ± 2.9 14.5 ± 5.0 p=0.4 
Platinum: - in tumors (nG/mG) 2.2 ± 1.9 5.1 ± 4.8 p=0.06 
 - ratio tumor/ left liver lobe 14.5 ± 6.6 43.4 ± 42.9 p=0.04 
Table-2: Mean platinum concentration (nG/mG) in liver tumors according to the type 
of emulsion injected and according to the delay before sacrifice. 
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Figures legends: 
Figure-1: Confocal scanning laser microscopy of Pickering-emulsion. Nanoparticules 
appears in blue (rhodamine) and surrounded the dispersed aqueous droplets in the 
countinuous oily-phase (Lipiodol), confirming that nanoparticules adsorbed at the 
interface to stabilize the emulsion. 
Figure-2: Trans-Arterial Chemo-Embolization (TACE) with oxaliplatin in a New 
Zealand White rabbit: angiography in the celiac trunk (A) and in the left-hepatic artery 
(B), post-TACE MR scan (C) and resected liver (D) showing a 15 mM large VX2 liver 
tumor (white arrow). 
Figure-3: In-vitro release of platinum from the Lipiodol-emulsion and from Pickering 
emulsion : masse released (A) and percentage released (B). 
Figure-4: Platinum plasmatic pharmacokinetics after injection of the emulsions in the 
left hepatic arteries. 
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